Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Huge volume today. I would it’s not Andy and Kelly issuing more shares. They can be involved in such things, would be a violation of the SEC settlement.
Likely MMs playing games again. Based on the recent FDA update and the Walmart pitch, now would be the time to buy, not sell.
If this stays on the surgical supply level maybe, just maybe, our CEO won’t be able to screw up a Recovery Rx deal with a medical supply co because it’s not retail.
Email alert just went out regarding their post op 510k. They are predicting an answer in 1-2 weeks. FDA asked for some statistical clarification on 6/14 and the company submitted their answer today. This is apparently the second follow up question and second response by BIEL.
God willing this comes to pass. Best of luck to you.
Sorry, my bad. That is important, I misunderstood that section. Listened while driving.
Oh please, wasn’t the 8ka going to include the transcript? That’s already out on their website, largely irrelevant now as an updated 8k exhibit.
Months. Maybe a month or two to file it, at least 5-6 to get a final answer. I think it’s all for the best that it not be gender-specific, but don’t count on any aspirational FDA reply and decision timeline.
Experience had shown it takes many moons.
Agree. Wed should be interesting. Love the idea of a live q and a. And they even filed their 8k to make it official, so it’s kind of a nice blend between the SHACs and formal Nasdaq disclosures. This investor expects a summary pr (assuming all goes well) a few days afterwards.
IMO this will never go below $1. 40% quarter over quarter growth and 44% YOY.
The warrant/PO hangover and the low offering price will wear off and we’ll continue to report increasing revenue. Once we get a couple of quarters in, get a positive P/E and analysts start covering, this will take off. Tech analysts will feel right at home in that new Silicon Valley-style office space, look at the black and white numbers, and potential growth and away we go.
Just my opinion.
Call him, he’ll answer.
I’m still long and want the company and product to survive.
I want laws and regulations to be followed and for executives to meet all legal and ethical responsibilities.
It’s not happening and hasn’t for the last year at least going back to the SEC settlement and the botching of several lucrative deals.
I’m not hear to bash the company, just to stay an informed long.
Time for regime change, keep up the pressure. Give him a golden parachute and put him on a plane to Del Boca Vista. I don’t care, just get him out of there.
Paul should know better than to release this fraudulent garbage.
“Remolding” test is inaccurate. CVS stores don’t have molding. It’s also inaccurate to say that it was part of a “remodeling” program. Yes, we were included in their new wellness sections. It seems deliberately misleading to me if CVS offered to take it nationwide and Andy said no. If that’s the case, then describing this as a test that was limited to a remodeling program is arguably a securities disclosure violation. Him turning down a deal and not telling us about is debatable. Not telling us and mis categorizing it is a problem. That and misspelling the key word is unforgivable.
It’s a tell, a Freudian slip.
He’s choking on the lie. I’ve worked at jobs where I would have been fired for that type of public typo.
It’s a red flag that something is very wrong, like warm champagne at a deal closing.
At least our pressure seems to have been working, they pledged to be more communicative in the future.
I’ll settle for him obeying US securities laws in the ‘34 Act.
Staelin
Agree, the gender difference was ridiculous from the start, call that half the FDAs fault for stalling on behalf of their pill-pushing patrons, and half on BIEL for not seeing the gender differences before submitting.
Yes, the PR is frustrating because we go from countdown mode back to zero, but their 510k never should have been gender specific to begin with.
How many macho athletes are going to use a device cleared, or initially cleared, only for women. It seems silly, but the FDA lead us down a rabbit hole and I’m glad we are getting out, better late than never.
Hopefully Andy and his daughter are forced out and Ed comes back.
What if we get a new CEO in if let’s say theoretically that it came out that he had dementia or some ulterior self-destructive motive.
New CEO (Ed or Keith) steps in and rings those guys up saying “sorry about the old guy, he has good days and bad ... now let’s get down to business and make some money together while doing good at the same time.”
Understood, thanks for your detailed post.
Yes, I do recall the timeline for shelf space in big box retailers with planogram decisions being made in October for products to hit the shelves early the following year.
Hopefully with the opiate epidemic raging in much of Walmart’s rural and suburban markets, they can see the good PR possibilities as well as the profits and get this thing fast-tracked for at least a limited rollout before 2020. But yes, I agree that in the real world it’s early 2020 and that’s assume things move forward in a straight line and pick up speed after the initial meeting.
Yup, it’s an initial meeting and Andy can find out a way to screw this up - up until contracts are signed and planograms finalized in October.
Give us this one win, Andy please.
For old times sake.
We know those due dates are not usually honored by the FDA with the way they manage the game clock. End of summer is my guess.
My hunch is they will both be approved, which would be great.
Please spell it out. I see the insole partnership now.
Completely agree. In a vacuum the PR is a great one.
Seen through the lens of years of PRs during which our sales declined quarter after quarter and big deals were never closed, it’s more of the same.
I hope the CEO says yes to this one. It won’t erase all of the waste we’ve seen, but a nationwide deal putting ActiPatch in Walmart across the country is going to make a big impact in our quarterly numbers.
Chompie, I’m not sure what your background is or how long you’ve been here. But I’ll give you the benefit of the doubt and assume you don’t work for the company.
Steve has earned the right to raise legitimate concerns. All companies are answerable to shareholders and that includes active shareholder who post on message boards and spend free time and money promoting the company’s products. Those of us who have been here 10 plus years have been more than patient, and many of us relatively recently ran out of patience since 2017 and have gotten more critical.
Anyone who has zero complaints has been pounding flavor-aide in a jungle somewhere.
In a true publicly traded company. Andy would have been voted out if it was revealed that he repeatedly said no to deals that would have produced handsome returns to shareholders.
And oh yeah, and there’s that little SEC issue that he hung around our necks like a lead albatross. Come to think of it, isn’t he supposed to be banned? So yeah, complaints are valid.
Nice to see Paul’s still around too.
Largest retailer in the US is Walmart. the question is will Andy say yes to a deal.
Glad to hear Keith is alive, well, still working on deals and not disappeared.
Let’s be blunt: Q1 numbers are horrific. Even worse than I expected and I wasn’t expecting much. The only positive there is the same amount of deferred revenue.
It’s hard to understand how we are making less money after the US clearances than we were before internationally.
While many companies get in trouble for inflating their quarterly numbers by cooking the books, it’s almost like the opposite is happening here.
Hard to understand how the numbers could be this bad in the midst of CVS rollout and modest expansion.
I’m not going anywhere, but I’m at a loss to explain how this company’s doing so poorly.
The buck stops at the CEO, President and Chairman of the Board - our Andy Whelan.
Bring back Ed Staelin for god sakes or sell this company to the highest bidder and end our misery.
It’s almost comical now. I’d laugh if I hadn’t poured thousands into it.
Crab cakes man, Maryland. Maryland blue crab with Old Bay Seasoning. Are the Orioles or the Nats playing today? There’s that too.
Probably, like Blackfish, super size me, or Food Inc.
Mostly true some exaggeration.
Wildest allegations will involve former employees disgruntly posting on stock message boards.
Or not, that’s controversial for some reason and will probably get this post deleted.
Send me a PM please with private email. I can’t respond bc I don’t have PM, but I’ll send you my info via gmail.
I can’t find that post, can you link it please?
Do you GGG have a plan? I’m not selling, I’ll see it go to zero or over a penny, no middle ground for me at this point.
The DD is great as far as it goes, but if the Whelans are the stumbling block to all good things, how do you see this ending? I’m assuming you have some plan or hope or you wouldn’t be here.
I believe you and it’s so so so disappointing. You invest and your patient and defend and support the company however you can and then they turn down the best opportunities we’ve had for the past decade? I believe you, but I hope it’s not true somehow.
Awesome, I’ll read them.
Where’s the GGG board now, last post I see is from June 2018. Please post.
Read my mind. Force a vote and get all new leadership.
I’ll research it and get back to you.
What’s the best way to separate the Whelans from this company (apparently the SEC a settlement was not enough) without them destroying it on the way down.
Proxy fight where shareholders reach out to board members and vote in new leadership?
We need Sree, the good doctor, and Keith, and Ed Stahlin, and no one else.
While I still think Andy has some legitimate reason for holding off on these deals, assuming it’s correct, (I think he’s waiting on full clearance), he’s waited way way too long and it’s really hurt the company.
How long does the patent run? Till 2023? That seemed like more than enough time back in 2012, but no more. We are no where near being a household name.
I’m all for a proxy fight and exercising all legal remedies as shareholders. We’ve got to pry it loose from the whelans. What do we have to lose?
Us OTC shareholders can unite and reach out to the institutional holders and vote these guys out.
Agree with almost everything.
Agree with how game-changing it is, but Bayer or J and J or the Sackler family could jump right back in the picture.
It’s not as if it was us or Monsanto. They are in a different stratosphere. Did it affect our prospects negatively? Maybe?
How good is our info about Bayer (or let’s just say Dr. Scholls). Is that deal truly dead, or is that based on some second hand repetition of an email or discussion with company personal that legally speaking should have been made public if it actually happened?
I’m always expecting to be disappointed, my expectations are slightly north of a liquidation bankruptcy.
But some tiny sliver of increase due to CVS rollout, or even a substantive footnote on the expansion from 200 to 300 plus stores would be very welcome. I’ve been here to long to be truly disappointed, a note about a company delivery van being repo-d wouldn’t surprise me.
Where oh where is Q1? I check the OTC site, anyone else know where it would be. I don’t think this is the death knell of the company, I seem to recall it’s been a day or two late (in terms of when the public sees it) in the past.
But this might actually be a decent quarter with CVS. If it’s dismal as usual it’ll look like an accounting trick so they can keep reporting a loss for tax purposes.
How could sales go down yet again with CVS rollout?